References
- Stanley FJ, Blair E, Alberman E. Cerebral palsies: Epidemiology & causal pathways. Mac Keith Press, London 2000
- Graham HK. Botulinum toxin A in cerebral palsy: Functional outcomes. The Journal of Pediatrics 2000; 137: 300–303
- Henderson A, Pehoski C. Hand function in the child. Foundations for remediation. Mosby, St. Louis, MO 1995
- De Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proceedings of the National Academy of Sciences (USA) 1999; 96: 3200–3205
- Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: Preliminary investigation. Journal of Pediatric Orthopaedics 1993; 13: 489–495
- Jefferson RJ. Botulinum toxin in the management of cerebral palsy. Developmental Medicine and Child Neurology 2004; 46: 491–499
- Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb: A double-blind trial. Developmental Medicine and Child Neurology 1997; 39: 185–193
- Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. The Journal of Pediatrics 2000; 137: 331–337
- Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. American Journal of Physical Medicine and Rehabilitation 2000; 79: 53–59
- Hurvitz EA, Conti GE, Brown SH. Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Archives in Physical Medicine and Rehabilitation 2003; 84: 444–454
- Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ. Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity. American Journal of Physical Medicine and Rehabilitation 2003; 82: 284–289
- Autti-Rämö I, Larsen A, Peltonen J, Taimo A, von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000; 31: 4–8
- Wallen MA, O’Flaherty SJ, Waugh M-CA. Functional outcomes of intramuscular botulinum toxin type A in the upper limbs of children with cerebral palsy: A phase II trial. Archives in Physical Medicine and Rehabilitation 2004; 85: 192–200
- Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy 1987; 67: 206–207
- Eliasson A-C, Ekholm C, Carlstedt T. Hand function in children with cerebral palsy after upper-limb tendon transfer and muscle release. Developmental Medicine and Child Neurology 1998; 40: 612–621
- Graham HK, Aoki KR, Autti-Rämö I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Jr, Guyer BM, Heinen F, Holton AF. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait and Posture 2000; 11: 67–79
- Haley SM, Coster SJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. Pediatric evaluation of disability inventory (PEDI): Development, standardization, and administration manual. New England Medical Centre and PEDI Research Group, Boston 1992
- Randall MJ, Johnson LM, Reddihough DS. The Melbourne assessment of unilateral upper limb function. Royal Children's Hospital, MelbourneAustralia 1999
- House J, Gwathmey F, Fidler M. A dynamic approach to the thumb-in-palm deformity in cerebral palsy. The Journal of Bone and Joint Surgery 1981; 63-A: 216–225
- Maloney FP, Mirrett P, Brooks C, Johannes K. Use of the goal attainment scale in the treatment and ongoing evaluation of neurologically handicapped children. The American Journal of Occupational Therapy 1978; 32: 505–510
- Eliasson A-C, Krumlinde-Sundholm L, Shaw K, Wang C. Effects of constraint-induced movement therapy in young children with hemiplegic cerebral palsy: An adapted model. Developmental Medicine and Child Neurology 2005; 47: 266–275
- Page SJ, Elovic E, Levine P, Sisto SA. Modified constraint-induced therapy and botulinum toxin A: A promising combination. American Journal of Physical Medicine and Rehabilitation 2003; 82: 76–80
- Herrmann J, Geth K, Mall V, Bigalke H, Mönting Schulte J, Linder M, Kirschner J, Berweck S, Korinthenberg R, Heinen F, Fietzek UM. Clinical impact of antibody formation to botulinum toxin A in children. Annals of Neurology 2004; 55: 732–735